Achieve Life Sciences Advances Cytisinicline Development

Achieve Life Sciences ( (ACHV) ) has released its Q2 earnings. Here is a breakdown of the information Achieve Life Sciences presented to its investors.

Achieve Life Sciences, a late-stage specialty pharmaceutical company, is focused on developing and commercializing cytisinicline for nicotine dependence and smoking cessation. In its second quarter of 2025, Achieve Life Sciences reported significant progress, including the submission of a New Drug Application (NDA) for cytisinicline to the FDA, a strategic partnership with Omnicom for a streamlined launch strategy, and a successful public offering raising $49.3 million. Key highlights include the completion of FDA long-term exposure requirements for cytisinicline, publication of positive Phase 3 trial results, and a strong financial position with $55.4 million in cash and equivalents. The company reported operating expenses of $12.6 million and a net loss of $12.7 million for the quarter. Looking ahead, Achieve Life Sciences is poised to advance cytisinicline through regulatory processes and potential commercialization, with a focus on addressing the critical public health need for effective smoking cessation treatments.